9.14
-0.235(-2.51%)
Currency In USD
| Previous Close | 9.37 |
| Open | 9.33 |
| Day High | 9.43 |
| Day Low | 8.62 |
| 52-Week High | 11.06 |
| 52-Week Low | 2.28 |
| Volume | 72,211 |
| Average Volume | 113,954 |
| Market Cap | 76.84M |
| PE | -2.42 |
| EPS | -3.78 |
| Moving Average 50 Days | 7.12 |
| Moving Average 200 Days | 4.62 |
| Change | -0.24 |
If you invested $1000 in Clene Inc. (CLNN) since IPO date, it would be worth $46.85 as of October 30, 2025 at a share price of $9.135. Whereas If you bought $1000 worth of Clene Inc. (CLNN) shares 5 years ago, it would be worth $42.1 as of October 30, 2025 at a share price of $9.135.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Clene to Participate in a Panel Discussion at the Maxim Growth Summit
GlobeNewswire Inc.
Oct 15, 2025 12:30 PM GMT
SALT LAKE CITY, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondria
Clene Presents New Clinical Data at ECTRIMS 2025 Meeting Demonstrating CNM-Au8® Improves Brain Energy Metabolism in Multiple Sclerosis Patients
GlobeNewswire Inc.
Sep 25, 2025 12:00 PM GMT
Late-breaking clinical data presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis Across non-active progressive MS (primary progressive and secondary progressive MS), relapsing MS, and Parkinson’s d
Clene Presents Preclinical Data Supporting CNM-Au8® for the Treatment of Parkinson’s Disease
GlobeNewswire Inc.
Sep 04, 2025 12:30 PM GMT
Novel human preclinical neuronal model for Parkinson’s disease demonstrated CNM-Au8’s ability to improve mitochondrial health, restore cellular metabolism, reduce inflammation, and normalize dysregulated gene expression in both familial and sporadic